Tapan Kadia, MD
Enriched profileProfessor, Department of Leukemia, Division of Cancer Medicine (Ashbel Smith Professor of Leukemia) · The University of Texas MD Anderson Cancer Center
Tapan Kadia is Professor, Department of Leukemia, Division of Cancer Medicine (Ashbel Smith Professor of Leukemia) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,816 publications with 33,581 citations (h-index 91); ClinicalTrials.gov lists 30 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Tapan Kadia, M.D., is Professor, Department of Leukemia, Division of Cancer Medicine (Ashbel Smith Professor of Leukemia) at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,816 publications with 33,581 citations (h-index 91), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 30 registered clinical trials, industry payments reported by 30 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Acute Myeloid Leukemia Research
- 30 registered trials on ClinicalTrials.gov
- Open Payments reporting from 30 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 226 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 526.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 30 registered studies on ClinicalTrials.gov. The most recent:
- Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
Sponsor: M.D. Anderson Cancer Center
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year202511 payments$18,141openpaymentsdata.cms.gov ↗
- Hikma Pharmaceuticals USAProgram year202510 payments$12,725openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.3%BCL-2 Inhibitor26.6%Venclexta100%Part D≥13 patientsKinase inhibitor26.1%Bosulif39%Calquence33%Imbruvica29%Part D<11 patientsAnti-infectives
35.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.6%Valacyclovir100%Part D≥14 patientsFluoroquinolone Antibacterial8.5%Levofloxacin100%Part D<11 patientsSensory organs
6%Fluoroquinolone Antibacterial6%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
Article2026 - Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
American journal of hematology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Acute myeloid leukemia: current progress and future directions761 citations2021
- 03
- 04Ibrutinib and Venetoclax for First-Line Treatment of CLL504 citations2019
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/tapan-kadia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/tapan-kadia-66564b7
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
faculty.mdanderson.org/profiles/tapan_kadia.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/mdandersoncancercenter_meet-leukemia-exert-dr-tapan-kadia-activity-6954795496020328450-OqPR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
vjhemonc.com/speaker/tapan-kadia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - X / Twitter
x.com/MDAndersonNews/status/1611538358282371073
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Director
T-cell LPD and Aplastic Anemia Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Co-Leader
AML Section
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Co-Leader
Section of Developmental Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- OncLive contributor/interviewee page -- video interviews on AML topics including uproleselan in relapsed/refractory AML
E-selectin as a treatment target, and IRAK4 pathway inhibition
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- Contributor
Oncology News Central
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologynewscentral.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center